26
Participants
Start Date
November 12, 2018
Primary Completion Date
December 6, 2021
Study Completion Date
June 7, 2023
Tremelimumab
"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
Georgetown University, Washington D.C.
University of North Carolina at Chapel Hill, Chapel Hill
Winship Cancer Institute of Emory University, Atlanta
University of Kansas Medical Center Research Institute, Inc., Westwood
Huntsman Cancer Institute University of Utah, Salt Lake City
Dana Farber- Partners Cancer Care, Inc, Boston
Ichan School of Medicine at Mount Sinai, New York
Collaborators (1)
AstraZeneca
INDUSTRY
Matthew Galsky
OTHER